A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma

Leukemia and Lymphoma

Volumn 55, Issue 12, 2014, Pages 2761-2768

  Goy, André ^a   Hernandez Ilzaliturri, Francisco J ^b   Kahl, Brad ^c   Ford, Peggy ^a   Protomastro, Ewelina ^a   Berger, Mark ^d  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d TEVA PHARMACEUTICALS   (Israel)

Author keywords

Bortezomib; Chemotherapeutic approaches; Drug resistance; Lymphoma and Hodgkin disease; Mantle cell; Obatoclax

Indexed keywords

BORTEZOMIB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; ETOPOSIDE; FAMOTIDINE; FLUDARABINE; IFOSFAMIDE; LORAZEPAM; OBATOCLAX; PARACETAMOL; RITUXIMAB; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEIN BCL 2; PYRAZINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; ATAXIA; BACTEREMIA; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER RECURRENCE; CATHETER INFECTION; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLOSTRIDIUM INFECTION; CONFUSION; CONSTIPATION; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENTEROCOLITIS; FACE EDEMA; FEMALE; HEADACHE; HICCUP; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOMAGNESEMIA; HYPOTENSION; MALE; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; OPEN STUDY; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PREMEDICATION; PROGRESSION FREE SURVIVAL; PRURITUS; RECOMMENDED DRUG DOSE; SEPSIS; SIDE EFFECT; SOMNOLENCE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; DISEASE COURSE; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; BORTEZOMIB; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; PYRROLES; TREATMENT OUTCOME;

EID: 84910036348     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.907891     Document Type: Article

References (39)

1. LaCasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012;119:2093-2099.
2. Goy A, Kahl B. Mantlecell lymphoma:the promiseofnewtreatment options. Crit Rev Oncol Hematol 2011; 80: 69-86.
3. Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008;113:791-798.
4. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7: 750-762.
5. Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011;117:26-38.
6. Katzenberger T, Petzoldt C, Holler S, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006;107:3407.
7. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185-197.
8. Gladden AB, Woolery R, Aggarwal P, et al. Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene 2006;25:998-1007.
9. Lovec H, Grzeschiczek A, Kowalski MB, et al. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J 1994;13:3487-3495.
10. Hofmann WK, de Vos S, Tsukasaki K, et al. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 2001;98:787-794.
11. Martinez N, Camacho FI, Algara P, et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003; 63: 8226-8232.
12. European public assessment report (EPAR) for Torisel [Internet]. London, UK: European Medicines Agency; 2012. Available from: http://www.ema.europa.eu/ema/index.jsp?curl = pages/medicines/human/medicines/000799/human-med-001098.jsp & mid = WC0b01 ac058001d124
13. FDA approves bortezomib (Velcade) for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy [Internet]. Silver Spring, MD: US Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2006 [updated 2009 May 21]. Available from: http://www.fda.gov/AboutFDA/CentersOf ces/Of ceofMedicalProductsandTobacco/CDER/ucm094929.htm
14. Lenalidomide [Internet]. Silver Spring, MD: US Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2013. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm355438.htm?source=govdelivery
15. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507-516.
16. Belch A, Kouroukis CT, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007; 18: 116-121.
17. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867-4874.
18. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-675.
19. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-684.
20. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006;24:2105-2112.
21. Perez-Galan P, Roue G, Villamor N, et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006;107:257-264.
22. Willis SN, Chen L, Dewson G, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev2005;19:1294-1305.
23. Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 2007;67:5418-5424.
24. Podar K, Gouill SL, Zhang J, et al. A pivotal role for Mcl-1 in bortezomib-induced apoptosis. Oncogene 2008; 27: 721-731.
25. Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007; 104:19512-19517.
26. Zhai D, Jin C, Satterthwait AC, et al. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 2006;13:1419-1421.
27. Ackler S, Mitten MJ, Foster K, et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol 2010; 66:869-880.
28. Brem EA, Tudium K, Khubchandani S, et al. Distinct cellularand therapeutic Effects of obatoclax in rituximab-sensitive and-resistant lymphomas. Br J Haematol 2011; 153: 599-611.
29. Paoluzzi L, Gonen M, Bhagat G, et al. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 2008; 112: 2906-2916.
30. Paoluzzi L, Gonen M, Gardner JR, et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic Effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 2008;111:5350-5358.
31. Perez-Galan P, Roue G, Villamor N, et al. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007; 109: 4441-4449.
32. Schimmer AD, O'Brien S, Kantarjian H, et al.A phaseI studyof the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:8295-8301.
33. Cheson BD, Horning SJ, Coifer B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
34. Parikh SA, Kantarjian H, Schimmer A, et al. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelof brosis. Clin Lymphoma Myeloma Leuk 2010;10:285-289.
35. O'Brien SM, Claxton DF, Crump M, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009;113:299-305.
36. Touzeau C, Dousset C, Bodet L, et al. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents. Clin Cancer Res 2011;17:5973-5981.
37. Rooswinkel RW, van de Kooij B, Verheij M, et al. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bf-1, or Bcl-B. Cell Death Dis 2012;3:e366.
38. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-3428.
39. Varadarajan S, Vogler M, Butterworth M, et al. Evaluation and critical assessment of putative MCL-1 inhibitors. Cell Death Differ 2013;20:1475-1484.